News and Comments

Takeda Acquires Ariad for $5.2 Billion

  Monday, January 09, 2017

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion, representing a premium of approximately 75 percent over ARIAD’s closing price on January 6, 2017. More...

Halozyme's PEGPH20 Trial Results Are Worth Appreciating Not Doubting

  Friday, January 06, 2017

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center clinical trial of its PEGPH20 in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer.  More...

The FDA Manufacturing Issues. Why Portola Rallied but Is Still Way Undervalued?

  Monday, December 26, 2016


Prohost Take on What's Going on in the Drug Sector

  Thursday, December 08, 2016

President Elect Trump was quoted in a Time person of the year as saying “I am going to bring down drug prices.” The President Elect did not say he is going to bring down the drug producing and developing firms.  More...

Cempra Stock has Been Cremated. Will Today's Good News Resurrect It?

  Monday, November 07, 2016

The nature the Presidential Election this time is weighing on investors’ chests and minds and mood and decisions. The stocks are typically reflecting investors’ inability to reason or make rational selection. Many are waiting for the election results to see whether they sell their portfolios or add to them. Negativity is the outcome fuelled by pessimism and by the simultaneous surfacing of articles and biographies of high ranking officials – all point to that political games are dominating every aspect of our lives, including the directions of our stocks’ moves.   More...

Regeneron and Sanofi Rheumatoid Arthritis Drug is Still Extremely Promising

  Monday, October 31, 2016

Regeneron (REGN) and Sanofi informed that the FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sarilumab. The drug  is an investigational interleukin-6 receptor (IL-6R) antibody for adult patients with moderately to severely active rheumatoid arthritis (RA). More...

Why We Are Ignoring the Temporary Selling of NKTR. See Also: Agenus Adjuvant in GSK Successful Shingles Vaccine

  Wednesday, October 19, 2016

There is nothing wrong with Nektar Therapeutics (NKTR). The stock is temporarily underperforming as traders are practicing their conviction that they must sell when a firm finances through dilution. The traders practice this law of thumb regardless of whether the financing aims at bringing wealth or invites for a catastrophe. We believe Nektar is walking the road towards creating wealth and growth through continued development of breakthrough products.    More...

Senator Sanders and Ariad

  Monday, October 17, 2016

Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the firm’s drug Iclusig (ponatinib) on Twitter. More...

A Promising Strategic Agreement Between A Large and A Small Biotech Firms.

  Thursday, October 13, 2016

When plenty of news comes out of the biotech sector, we are left with no option but prioritizing. Connecting the dots also might serve some purpose, including smelling take-over possibilities that make sense or contribute to improvements of the treatments and of firms’ finances. Prioritizing comprises selecting as much as possible the most concrete subjects that are safe to explore.  More...

Alnylam: Some Acted Without Listening and Some Listened But Did Not Believe

  Thursday, October 06, 2016

Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with cardiomyopathy (hATTR-CM) treated with Alnylam’s (ALNY) RNAi –based drug revusiran, The firm requested that the Data Monitoring Committee (DMC) review the reports and the Clinical trial data on an unblinded basis. After reviewing the reports, the DMC advised suspending the dosing of revusiran.   More...

Recent Postings



NOVOCURE (NVCR) Multiple Myeloma Auspex (ASPX) NANTKWEST (NK) Telaprevir CRISPR Therapeutics (CRSP) ImmunoGen (IMGN) Prosensa (RNA) Trastuzumab-DM1 Seattle Genetics (SGEN) Idenix (IDIX) Jazz Pharmaceuticals (JAZZ) Array Pharmaceuticals (ARRY) ABBVIE (ABBV) SYNTA (SNTA) OncoCyte (OCX) Dendreon (DNDN) SUNESIS PHARMACEUTICALS (SNSS) Revlimid (lenolidamide) LEXICON (LXRX) Intrexon (XON) Advaxis (ADXS) Ariad (ARIA) Biocryst (BCRX) Human Genome Sciences (HGSI) Valeant Pharmaceuticals International (VRX) IDERA (IDRA) HALOZYME (HALO) MODERNA NEUROCRINE (NBIX) Alnylam (ALNY) GlaxoSmithKline (GSK) Benlysta (belimumab) Prolor Biotech (PBTH) AERIE PHARMACEUTICALS Sanofi-Aventis (SAN) ZALTRAP™ Incyte (INCY) galapagos (GLPG) AGOS (ARGS) Sangamo (SGMO) PORTOLA (PTLA) Velcade (bortezomib) Theravance (THRX) Zerenex Illumina (ILMN) GUARDIAN HEALTH Ionis (IONS) BIOMARIN (BMRN) Inovio (INO) Regeneron (REGN) Bellicum (BLCM) Roche (ROCHE) Galena (GALE) ARCA (ABIO) Amgen (AMGN) Onyx (ONXX) JUNO (JUNO) Sanofi (SNY) Abbott Laboratories (ABT) ISIS (ISIS) Sarepta (SRPT) Vitae Pharmaceuticals (VTAE) C4 Therapeutics KERYX (KERX) Dynavax (DVAX) RenenxBio (RGNX) VANDA (VNDA) Rapamune Agenus (AGEN) REGULUS (RGLS) Intercept (ICPT) OSI (OSIP) Herceptin CompuGen (CGEN) Pluristem (PSTI) Anadys (ANDS) PTC Therapeutics (PTCT) Theravance Bio Pharma (TBPH) Gilead (GILD) Adaptimmune (ADAP) Anacor (ANAC) Vertex (VRTX) Alder Biopharmaceuticals (ALDR) Micromet (MITI) Tysabri ACADIA (ACAD) TOKAI (TKAOI) Human Longevity (HLI) Biogen Idec (BIIB) NEKTAR (NKTR)) Merck (MRK) AstraZeneca (AZN) KITE (KITE) INNOVIVA (INVA) Bristol-Myers Squibb (BMY) Editas (EDIT) Ocular Therapeutix (OCUL) Sanofi (SNA) CEMPRA (CEMP) Ziofpharm (ZIOP) Ridaforolimus JOUNCE THERAPEUTICS (JNCE) ARGOS (ARGS) SERES THERAPEUTICS (MCRB) Elan (ELN) Aimmune Therapeutics (AIMT) Sequenom (SQNM) Agenus (AGEN ADVENTRIX (ANX) Roche (RHHBY) Xoma (XOMA) Spike Therapeutics (ONCE) Exelixis (EXEL) Cytokinetics (CYTK) Global Cell Therapeutics (GBT) Endometrial Cancer Mirati Therapeutics (MRTX) Intermune (ITMN) Genentech